Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Jensen

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
BMC Pharmacology|December 4, 2004
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cellsLars H Jensen, Marielle Dejligbjerg, Lasse T Hansen, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|June 8, 2023
Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273: A Danish Population-Based Cohort StudyPer Damkier, Brian Cleary, Jesper Hallas, et al.
Electrophoresis|August 19, 2010
Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostatHans Christian Beck, Jørgen Petersen, Søren Jensby Nielsen, et al.
FEBS Letters|June 5, 2002
Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alphaIrene Wessel, Lars H Jensen, Axelle Renodon-Corniere, et al.
Molecular Pharmacology|April 16, 2003
Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alphaAxelle Renodon-Cornière, Tina K Sørensen, Peter B Jensen, et al.
Biochemical Pharmacology|August 9, 2003
A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alphaLars H Jensen, Axelle Renodon-Cornière, Karin C Nitiss, et al.
Molecular Pharmacology|April 19, 2002
Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibitionLars H Jensen, Axelle Renodon-Corniere, Irene Wessel, et al.
The Journal of Biological Chemistry|January 14, 2005
Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysisJerrylaine Vaughn, Shengli Huang, Irene Wessel, et al.
Toxicology|November 18, 2008
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathyElke Martin, Annemette Vinding Thougaard, Morten Grauslund, et al.
The Journal of Biological Chemistry|March 24, 2004
A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cellsJerrylaine V Walker, Karin C Nitiss, Lars H Jensen, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
BMC Pharmacology|December 4, 2004
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cellsLars H Jensen, Marielle Dejligbjerg, Lasse T Hansen, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|June 8, 2023
Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273: A Danish Population-Based Cohort StudyPer Damkier, Brian Cleary, Jesper Hallas, et al.
Electrophoresis|August 19, 2010
Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostatHans Christian Beck, Jørgen Petersen, Søren Jensby Nielsen, et al.
FEBS Letters|June 5, 2002
Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alphaIrene Wessel, Lars H Jensen, Axelle Renodon-Corniere, et al.
Molecular Pharmacology|April 16, 2003
Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alphaAxelle Renodon-Cornière, Tina K Sørensen, Peter B Jensen, et al.
Biochemical Pharmacology|August 9, 2003
A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alphaLars H Jensen, Axelle Renodon-Cornière, Karin C Nitiss, et al.
Molecular Pharmacology|April 19, 2002
Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibitionLars H Jensen, Axelle Renodon-Corniere, Irene Wessel, et al.
The Journal of Biological Chemistry|January 14, 2005
Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysisJerrylaine Vaughn, Shengli Huang, Irene Wessel, et al.
Toxicology|November 18, 2008
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathyElke Martin, Annemette Vinding Thougaard, Morten Grauslund, et al.
The Journal of Biological Chemistry|March 24, 2004
A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cellsJerrylaine V Walker, Karin C Nitiss, Lars H Jensen, et al.
Pageof 3